MILRINONE LACTATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Milrinone Lactate, and when can generic versions of Milrinone Lactate launch?
Milrinone Lactate is a drug marketed by Baxter Hlthcare Corp, Caplin, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Hikma Farmaceutica, Hospira, Intl Medicated, Meitheal, Mylan Institutional, Shandong, Eugia Pharma, Woodward, B Braun, Baxter Hlthcare, and West-ward Pharms Int. and is included in twenty-five NDAs.
The generic ingredient in MILRINONE LACTATE is milrinone lactate. There are nine drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the milrinone lactate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Milrinone Lactate
A generic version of MILRINONE LACTATE was approved as milrinone lactate by FRESENIUS KABI USA on May 28th, 2002.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MILRINONE LACTATE?
- What are the global sales for MILRINONE LACTATE?
- What is Average Wholesale Price for MILRINONE LACTATE?
Summary for MILRINONE LACTATE
US Patents: | 0 |
Applicants: | 16 |
NDAs: | 25 |
Finished Product Suppliers / Packagers: | 9 |
Raw Ingredient (Bulk) Api Vendors: | 28 |
Clinical Trials: | 5 |
Drug Prices: | Drug price information for MILRINONE LACTATE |
DailyMed Link: | MILRINONE LACTATE at DailyMed |
Recent Clinical Trials for MILRINONE LACTATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Shanghai Children's Medical Center | Phase 3 |
Ottawa Heart Institute Research Corporation | Phase 4 |
University of Pennsylvania | N/A |
Pharmacology for MILRINONE LACTATE
Drug Class | Phosphodiesterase 3 Inhibitor |
Mechanism of Action | Phosphodiesterase 3 Inhibitors |